DAX24.889 +0,2%Est505.982 -0,5%MSCI World4.343 -0,1%Top 10 Crypto8,6000 +2,1%Nas22.597 -2,0%Bitcoin56.680 +1,6%Euro1,1874 ±0,0%Öl67,71 +0,2%Gold4.988 +1,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Siemens 723610 Deutsche Telekom 555750 Siemens Energy ENER6Y Rheinmetall 703000 SAP 716460 Amazon 906866 Mercedes-Benz Group (ex Daimler) 710000 NVIDIA 918422 BASF BASF11 Lufthansa 823212 Microsoft 870747 Heidelberg Materials 604700 Allianz 840400 Bayer BAY001 DroneShield A2DMAA
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Nach US-Inflationsdaten: DAX leicht im Plus -- Amazon im Bärenmarkt -- Delivery Hero von Talabat belastet -- pbb, Siemens, RWE, Rivian, Applied Materials, Adyen, Apple, Arista im Fokus
Top News
Airbnb: Premium-Strategie übertrifft Analystenerwartungen! Airbnb: Premium-Strategie übertrifft Analystenerwartungen!
US-Inflation sinkt im Januar US-Inflation sinkt im Januar
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Castle Biosciences Aktie

Kaufen
Verkaufen
26,40 EUR -0,40 EUR -1,49 %
FSE
31,96 USD -0,35 USD -1,08 %
BTT
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.795,99 Mio. EUR

KGV42,74Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2PNH3

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS14843C1053

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolCSTL

Castle Biosciences Aktien News

DatumMeistgelesen
BusinesswireCastle Biosciences to Highlight Clinical Value of IDgenetix® Test at Psych Congress 2023
BusinesswireCastle Biosciences to Participate in Upcoming Investor Conferences
BusinesswireNew Publication Highlights the Ability of the TissueCypher® Barrett’s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus
BusinesswireCastle Biosciences to Present at the Canaccord Genuity 43rd Annual Growth Conference
BusinesswireCastle Biosciences to Release Second Quarter 2023 Financial Results and Host Conference Call on Wednesday, Aug. 2
BusinesswireCastle Biosciences to Host Second Annual Castle Cares Charity Walk
BusinesswireCastle Biosciences Honored as an Arizona Top Workplace for the Second Consecutive Year
BusinesswireCastle Biosciences to Present New DecisionDx®-SCC and DecisionDx®-Melanoma Data at the American Head & Neck Society’s (AHNS) 11th International Conference on Head and Neck Cancer
BusinesswireStudy Data from Castle Biosciences’ Collaboration with the National Cancer Institute’s SEER Program Registries Published in JCO Precision Oncology
BusinesswireCastle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BusinesswireCastle Biosciences to Share New Data on DecisionDx®-Melanoma and DecisionDx®-UM at the 2023 ASCO Annual Meeting
BusinesswireIDgenetix® Shown to Significantly Improve Medication Response and Remission Rates in Patients with Major Depressive Disorder
BusinesswireCastle Biosciences Celebrates Skin Cancer Awareness Month
BusinesswireCastle Biosciences’ Abstracts at Digestive Disease Week (DDW) Annual Meeting Selected as "Posters of Distinction” by the American Gastroenterological Association (AGA) Institute Council
BusinesswireCastle Biosciences Opens New State-of-the-Art Laboratory in Pittsburgh
BusinesswireCastle Biosciences’ TissueCypher® Barrett's Esophagus Test Receives 2023 MedTech Breakthrough Award for Artificial Intelligence Innovation
BusinesswireCastle Biosciences Collaborates with IMPACT Melanoma to Provide Free Sunscreen to Cyclists Participating in the Bike MS: Texas MS 150 2023 Cycling Event
BusinesswireDecisionDx®-Melanoma Provides Improved Risk Stratification Over American Joint Committee on Cancer (AJCC) Staging Alone in Stage I Melanoma Patients
BusinesswireTissueCypher® Test Results Can Increase the Likelihood of Appropriate Management Decisions for Barrett’s Esophagus Patients with Low-Grade Dysplasia
BusinesswireCastle Biosciences to Release First Quarter 2023 Financial Results and Host Conference Call on Wednesday, May 3
BusinesswireCastle Biosciences to Present at the 22nd Annual Needham Virtual Healthcare Conference
BusinesswireCastle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
BusinesswireCastle Biosciences to Highlight Clinical Value of Its Skin Cancer Tests at the 2023 American Academy of Dermatology (AAD) Annual Meeting
BusinesswireCastle Biosciences’ Chief Financial Officer Frank Stokes Selected Among the Top 25 CFOs of Houston for 2023 by Finance & Investing
BusinesswireData Presentation at 2023 Winter Clinical - Miami™ Highlights Use of DecisionDx®-Melanoma to Guide SLNB Surgery Decisions in Head and Neck Tumors

Castle Biosciences News

Castle Biosciences News: auf dieser Seite finden Sie alle Castle Biosciences News und Nachrichten zur Castle Biosciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Castle Biosciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Castle Biosciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.